{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-26-008347","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2026-09-14T21:22:12+00:00","discovered_at":"2026-09-14T21:24:00.149921+00:00","generated_at":"2026-09-14T21:24:04.750489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pharma-Bio Serv Q3 revenue up ~$0.4M YoY; net loss narrows to $14K","bullets":["Q3 (ended July 31, 2026) revenue ~$2.3M, up ~$0.4M YoY; nine-month revenue ~$7.3M, up ~$0.5M YoY.","Q3 net loss of $14K, an ~$190K improvement YoY; nine-month net income ~$252K, up ~$352K YoY.","CEO Victor Sanchez credits client relationships and specialized compliance capabilities for improved performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-008347","json":"https://secwatch.observer/filing/0001654954-26-008347.json","markdown":"https://secwatch.observer/filing/0001654954-26-008347.md","text":"https://secwatch.observer/filing/0001654954-26-008347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426008347/0001654954-26-008347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426008347/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T21:24:04.750489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}